Novartis AG ADR Stock
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | -2.820% | 0.353% | 9.231% | 34.597% | 19.831% | 78.392% | 102.857% |
| Roche Holding AG ADR | -2.010% | -1.389% | 2.263% | 24.029% | 13.393% | 44.804% | 46.998% |
| Bayer AG ADR | 1.100% | -14.352% | -15.909% | 50.407% | 5.114% | -34.859% | -27.734% |
| Teva Pharmaceutical Industries Ltd ADR | -3.180% | -0.702% | -4.714% | 91.216% | 5.204% | 199.788% | 220.136% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weighed a large Vivtex partnership while
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
Many people aim to save at least $1 million for their retirement years to help supplement programs like Social Security. Whether this amount is enough or not, it's certainly much better than
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
Novo Nordisk (NYSE:NVO), a healthcare giant that develops and markets diabetes and obesity treatments, closed Monday at $39.63, down 16.43%. The stock fell after it announced CagriSema, its